CYV Intrinsic Valuation and Fundamental Analysis - Opthea Ltd

Watchlist Manager

Watchlist

Price on Oct 14: 0.011 AUD

Market Cap: AU$15m

Prices of ASX stocks are not being updated. The latest CYV price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value for Opthea Ltd.

Do our valuations actually work? See backtest results .

Fundamental Analysis

What Opthea Does

Biotechnology Health Care

Opthea Ltd is a biotechnology company that develops eye-disease medicines, with its main focus on treatments for retinal diseases such as wet age-related macular degeneration and diabetic macular edema. Its lead drug candidate is an injected therapy designed to stop abnormal blood vessel growth and fluid leakage in the eye, which are major causes of vision loss.

Headquarters: Australia AU
IPO date: Apr 9, 1985

Read the full company overview

How Opthea makes money

Eye disease drugs

Opthea develops drug candidates for eye diseases, with its main work focused on treatments for retinal conditions that can affect central vision.

Customers: The company works with eye doctors, hospitals, and clinical trial partners while it develops medicines that would be sold to patients through prescription channels if approved.
Revenue Model: At this stage, Opthea is mainly funded through research collaboration income, licensing or partnership payments if it signs them, and future sales of its approved drug products if any reach the market.

View Company Overview